Estimating the impact of improved management of haemophilia a on clinical outcomes and healthcare utilisation and costs

Table 1 Current Haemophilia A management characteristics

Characteristics		Algeria	Argentina	Chile	India	Malaysia	Mexico	Taiwan	Thailand
Income category [6]		LMIC	UMIC	HIC	LMIC	UMIC	UMIC	HIC	UMIC
PWHA, n [2, 7]		1,911	3,069	1,566	2,000^†	950	4,814	992	1,557
Patients with severe HA, %		90%	69%	30%	82%	59%	68%	72%	59%
Children, %		37%	33%	30%	30%	43%	38%	33%	75%
Current Practice	OD	62%	55%	74%	91%	50%	28%	28%	78%
	VLD SHL Px	0%	0%	0%	2%	0%	0%	0%	8%
	LD SHL Px	0%	0%	5%	7%	23%	0%	0%	14%
	ID SHL Px	38%	1%	21%	0%	19%	15%	15%	0%
	HD SHL Px	0%	38%	0%	0%	5%	0%	0%	0%
	Pers. SHL Px	0%	6%	0%	0%	0%	0%	0%	0%
	EHL Px	0%	0%	0%	0%	4%	57%	57%	0%
Home-Based Px (%)		65%	90%	90%	0%	86%	90%	85%	90%
Compliance (%)		100%	65%	75%	50%	80%	74%	95%	80%
OD annual bleeds^‡		36.0	17.5	25.0	17.5	12.0	33.0	31.9	22.0
Patients switched from OD (n)^††		209	157	25	290	21	78	4	130

Notes: ^†Estimated population of patients with haemophilia A in India (Tamil Nadu)^{; ‡}The estimated annual bleed rate of an adult patient with severe haemophilia A managed without prophylaxis (Px ABRs are estimated as a function of the reported OD ABR); ^††The switch population comprised 20% of the severe HA patients currently managed via an OD regimen
Abbreviations: EHL: extended half-life; HA: haemophilia A; HIC: high income country; ID: intermediate-dose; LD: low-dose; LMIC: low-middle income country; Pers.: personalised; Px: prophylaxis; PWHA: patients with haemophilia A; SHL: standard-half life; UMIC: upper-middle income country; VLD: very low-dose

ISSN: 1756-0500